Abstract
Long non-coding RNA (lncRNA) genes have well-established and important impacts on molecular and cellular functions. However, among the thousands of lncRNA genes, it is still a major challenge to identify the subset with disease or trait relevance. To systematically characterize these lncRNA genes, we used Genotype Tissue Expression (GTEx) project v8 genetic and multi-tissue transcriptomic data to profile the expression, genetic regulation, cellular contexts, and trait associations of 14,100 lncRNA genes across 49 tissues for 101 distinct complex genetic traits. Using these approaches, we identified 1,432 lncRNA gene-trait associations, 800 of which were not explained by stronger effects of neighboring protein-coding genes. This included associations between lncRNA quantitative trait loci and inflammatory bowel disease, type 1 and type 2 diabetes, and coronary artery disease, as well as rare variant associations to body mass index.
Original language | English |
---|---|
Pages (from-to) | 2633-2648.e19 |
Journal | Cell |
Volume | 184 |
Issue number | 10 |
DOIs | |
Publication status | Published - May 13 2021 |
Bibliographical note
Publisher Copyright:© 2021 Elsevier Inc.
Funding
We thank the Montgomery and Kirkegaard labs for their feedback on this work. The GTEx project was supported by the Common Fund of the Office of the Director of the National Institutes of Health (NIH) and by the National Cancer Institute , the National Human Genome Research Institute (NHGRI), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health , and the National Institute of Neurological Disorders and Stroke. We are thankful for support from a Stanford graduate fellowship and Bio-X Stanford interdisciplinary graduate fellowship (to O.M.d.G.); a National Science Foundation graduate research fellowship (to N.M.F.); NHLBI grant R01HL135313-01 (to A.S.R.); National Library of Medicine (NLM) training grant 5T15LM007033-36 (to T.Y.E.); NHLBI grant HHSN268201000029C and NHGRI grant 5U41HG009494 (to F.A. and K.G.A.); NIH grants R01GM122924 (to S.E.C. and T.L.) and 1K99HG009916-01 (to S.E.C.); Marie-Skłodowska Curie fellowship H2020 grant 706636 (to S.K.-H.); NIH grant R01HG010067 (to Y.P.); a Mr. and Mrs. Spencer T. Olin fellowship for women in graduate study (to A.J.S.); NIH grant R01MH109905 (to A.B.); the Searle Scholar Program (to A.B.); NIH grant R01MH101822 (to C.D.B.); NIH grants R01MH106842 , R01HL142028 , UM1HG008901 , and R01GM124486 (to T.L.); NIH grants R01MH107666 and P30DK020595 (H.K.I.); NIH grants R01HL109512 , R01HL134817 , R33HL120757 , and R01HL139478 (to T.Q.); the Chan Zuckerberg Foundation-Human Cell Atlas Initiative (to T.Q.); Stanford University School of Medicine (to K.K.); and NIH grants R01MH101814 (NIH Common Fund; GTEx Program) (to A.B. and S.B.M.), R01HG008150 (NHGRI; Non-Coding Variants Program) (to A.B. and S.B.M.), and R01AG066490 , R01HL142015 , U01HG009431 , and U01HG009080 (to S.B.M.). We thank the Montgomery and Kirkegaard labs for their feedback on this work. The GTEx project was supported by the Common Fund of the Office of the Director of the National Institutes of Health (NIH) and by the National Cancer Institute, the National Human Genome Research Institute (NHGRI), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke. We are thankful for support from a Stanford graduate fellowship and Bio-X Stanford interdisciplinary graduate fellowship (to O.M.d.G.); a National Science Foundation graduate research fellowship (to N.M.F.); NHLBI grant R01HL135313-01 (to A.S.R.); National Library of Medicine (NLM) training grant 5T15LM007033-36 (to T.Y.E.); NHLBI grant HHSN268201000029C and NHGRI grant 5U41HG009494 (to F.A. and K.G.A.); NIH grants R01GM122924 (to S.E.C. and T.L.) and 1K99HG009916-01 (to S.E.C.); Marie-Sk?odowska Curie fellowship H2020 grant 706636 (to S.K.-H.); NIH grant R01HG010067 (to Y.P.); a Mr. and Mrs. Spencer T. Olin fellowship for women in graduate study (to A.J.S.); NIH grant R01MH109905 (to A.B.); the Searle Scholar Program (to A.B.); NIH grant R01MH101822 (to C.D.B.); NIH grants R01MH106842, R01HL142028, UM1HG008901, and R01GM124486 (to T.L.); NIH grants R01MH107666 and P30DK020595 (H.K.I.); NIH grants R01HL109512, R01HL134817, R33HL120757, and R01HL139478 (to T.Q.); the Chan Zuckerberg Foundation-Human Cell Atlas Initiative (to T.Q.); Stanford University School of Medicine (to K.K.); and NIH grants R01MH101814 (NIH Common Fund; GTEx Program) (to A.B. and S.B.M.), R01HG008150 (NHGRI; Non-Coding Variants Program) (to A.B. and S.B.M.), and R01AG066490, R01HL142015, U01HG009431, and U01HG009080 (to S.B.M.). O.M.d.G. designed the study, conducted analyses, visualized data, and co-wrote the manuscript; D.C.N. conducted co-expression and ASE analyses. N.M.F. conducted outlier analysis and contributed to writing. M.J.G. conducted colocalization analysis. A.S.R. contributed to colocalization analysis. C.S. contributed to outlier analysis. T.Y.E. contributed to ASE analysis. F.A. generated QTL and ASE data. B.N. and J.X. contributed to QTL replication analyses. A.N.B. contributed to GWAS and colocalization analysis. S.E.C. generated ASE and tissue-sharing data. S.K.-H. generated tissue sharing data. Y.P. contributed to colocalization analysis. A.J.S. generated structural variant data. B.J.S. contributed to outlier analysis. C.D.B. and X.W. led trainees and contributed to GWAS and colocalization analysis. I.M.H. led trainees and contributed to structural variant data. A.B. contributed to outlier analysis. T.L. led trainees. H.K.I. led trainees and led the GWAS analysis team. K.G.A. generated data and provided oversight of the LDACC and pipelines. S.M. led trainees and contributed to QTL replication analyses. T.Q. and K.K. helped with data interpretation. S.B.M. designed the study, led trainees, and co-wrote the manuscript. F.A. is an inventor on a patent application related to TensorQTL; S.E.C. is a co-founder and chief technology officer at Variant Bio and owns stock in Variant Bio; T.L. is on the scientific advisory board of Variant Bio, Goldfinch Bio, and GSK and owns stock in Variant Bio; and S.B.M. is on the scientific advisory board of MyOme. All other authors report no competing interests.
Funders | Funder number |
---|---|
LDACC | |
Marie-Skłodowska Curie fellowship H2020 | |
National Science Foundation | R01HL135313-01 |
National Institutes of Health | |
National Institute of Mental Health | R01MH109905, R01MH101822, R01MH107666, R01MH106842 |
National Institute on Drug Abuse | |
National Heart, Lung, and Blood Institute | R01HL134817, R01HL139478, R01HL142028, R01HL142015, R33HL120757, R01HL109512 |
National Human Genome Research Institute | U01HG009080, R01HG008150, R01HG010067, U01HG009431, UM1HG008901 |
National Cancer Institute | |
National Institute of Neurological Disorders and Stroke | |
U.S. National Library of Medicine | HHSN268201000029C, 5U41HG009494, 1K99HG009916-01, R01GM122924, 5T15LM007033-36 |
School of Medicine, Stanford University | R01MH101814, R01AG066490 |
Horizon 2020 Framework Programme | 706636 |
Searle Scholars Program | R01GM124486, P30DK020595 |
ASJC Scopus Subject Areas
- General Biochemistry,Genetics and Molecular Biology